Detalhe da pesquisa
1.
The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination.
Nat Immunol
; 22(10): 1294-1305, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34556879
2.
Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques.
J Virol
; 94(6)2020 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-31896599
3.
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
J Virol
; 91(9)2017 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28179536
4.
Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates.
J Virol
; 89(16): 8525-39, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26041302
5.
Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
J Virol
; 89(12): 6462-80, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25855741
6.
Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial.
J Virol
; 87(3): 1708-19, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23175374
7.
Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
J Infect Dis
; 207(8): 1195-205, 2013 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22837492
8.
Expansion of the HSV-2-specific T cell repertoire in skin after immunotherapeutic HSV-2 vaccine.
medRxiv
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38352384
9.
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
J Infect Dis
; 206(3): 431-41, 2012 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22634875
10.
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.
N Engl J Med
; 361(23): 2209-20, 2009 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-19843557
11.
DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa.
J Virol
; 85(19): 9854-62, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21775454
12.
The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022.
Nat Commun
; 13(1): 5794, 2022 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36184631
13.
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.
Nat Commun
; 8: 15711, 2017 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28593989
14.
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
J Clin Oncol
; 23(35): 9008-21, 2005 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-16061912
15.
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.
Nat Med
; 22(7): 762-70, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27239761
16.
Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors.
Expert Rev Vaccines
; 3(4 Suppl): S75-88, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15285707
17.
Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.
Lancet Infect Dis
; 12(7): 531-7, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22652344
18.
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
AIDS Res Hum Retroviruses
; 28(11): 1444-57, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23035746
19.
Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors.
PLoS One
; 6(2): e16819, 2011 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21347234
20.
Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.
Nat Med
; 22(10): 1192, 2016 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27711066